Ogunrin Ao
Department of Medicine, Neurology Unit, University of Benin Teaching Hospital, Benin City, Nigeria.
Ann Med Health Sci Res. 2014 Jul;4(4):654-61. doi: 10.4103/2141-9248.139368.
Chronic medical disorders are often complicated by cognitive impairments, making medical intervention that can alleviate cognitive disturbances desirable. Vinpocetine enhances cerebral utilization of oxygen and glucose and consequently improves cerebral functions including memory.
This study assessed the efficacy of vinpocetine (Cognitol™) in improving memory and concentration in cognitively impaired patients.
A prospective analytical study of 56 cognitively impaired patients compared with age, sex and level of education matched 56 controls. Cognitive performance was assessed with the Short Blessed Test, which was pilot-tested. Baseline cognitive performances of the patients and controls were obtained and thereafter cognitive performances of the patients were assessed at 6 and 12 weeks after administration of vinpocetine at a dose of 5 mg twice-a-day. Comparative analysis of their performances at baseline was done using the Student t-test, while the improvement in patients' performances and effect of disease variables on cognitive performances were analyzed with one-way analysis of variance and likelihood ratio analysis respectively.
The mean (standard deviation) [SD] ages of the cognitively impaired patients (56/112) and controls (56/112) were 49.5 (18.9) and 53.8 (15.8) years respectively (P = 0.19; 95% confidence interval [CI]: 2.2-10.8). The pilot study yielded an optimal cut-off error score of 6 with a sensitivity of 71.4%, specificity of 96.4% and accuracy of 83.9%. Patients performed significantly worse than the controls (P < 0.001; 95% CI 6.7-11.4). There were significant improvements in memory and concentration with vinpocetine therapy (P < 0.05). The clinical variables of the patients had no effect on the trend of cognitive performances.
Vinpocetine was effective in improving memory and concentration of patients with epilepsy and dementia although the efficacy was minimal in demented patients.
慢性疾病常伴有认知障碍,因此能缓解认知紊乱的医学干预备受期待。长春西汀可提高大脑对氧气和葡萄糖的利用率,进而改善包括记忆在内的大脑功能。
本研究评估长春西汀(Cognitol™)对改善认知障碍患者记忆和注意力的疗效。
一项前瞻性分析研究,纳入56例认知障碍患者,并与年龄、性别和教育程度相匹配的56例对照者进行比较。采用经过预试验的简易精神状态检查表评估认知表现。获取患者和对照者的基线认知表现,之后给予患者每日两次、每次5 mg的长春西汀,在给药后6周和12周评估其认知表现。使用学生t检验对他们在基线时的表现进行比较分析,同时分别用单向方差分析和似然比分析来分析患者表现的改善情况以及疾病变量对认知表现的影响。
认知障碍患者(56/112)和对照者(56/112)的平均(标准差)年龄分别为49.5(18.9)岁和53.8(15.8)岁(P = 0.19;95%置信区间[CI]:2.2 - 10.8)。预试验得出最佳截断误差分数为6,灵敏度为71.4%,特异性为96.4%,准确性为83.9%。患者的表现显著差于对照者(P < 0.001;95% CI 6.7 - 11.4)。长春西汀治疗后,记忆和注意力有显著改善(P < 0.05)。患者的临床变量对认知表现趋势无影响。
长春西汀可有效改善癫痫和痴呆患者的记忆和注意力,尽管对痴呆患者的疗效甚微。